Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics (Nasdaq: AKBA) has granted stock options to three newly-hired employees as employment inducements. The options allow purchase of 20,000 shares of common stock at $1.66 per share, matching the closing price on October 31, 2024. These options vest over four years, with 25% vesting after one year and the remaining 75% vesting quarterly thereafter, contingent on continued employment. The options have a 10-year term and comply with Nasdaq Listing Rule 5635(c)(4).
Akebia Therapeutics (Nasdaq: AKBA) ha concesso opzioni su azioni a tre nuovi dipendenti come incentivo all'impiego. Le opzioni consentono l'acquisto di 20.000 azioni di azioni ordinarie a $1,66 per azione, corrispondente al prezzo di chiusura del 31 ottobre 2024. Queste opzioni maturano in quattro anni, con il 25% che matura dopo un anno e il restante 75% che matura trimestralmente successivamente, a condizione di un impiego continuato. Le opzioni hanno un termine di 10 anni e sono conformi alla Regola di Quotazione Nasdaq 5635(c)(4).
Akebia Therapeutics (Nasdaq: AKBA) ha concedido opciones sobre acciones a tres empleados recién contratados como incentivos laborales. Las opciones permiten la compra de 20,000 acciones de acciones comunes a $1.66 por acción, coincidiendo con el precio de cierre del 31 de octubre de 2024. Estas opciones se consolidan en cuatro años, con un 25% consolidándose después de un año y el 75% restante consolidándose trimestralmente a partir de entonces, sujeto a la continuación del empleo. Las opciones tienen un plazo de 10 años y cumplen con la Regla de Cotización Nasdaq 5635(c)(4).
Akebia Therapeutics (Nasdaq: AKBA)는 새로 채용된 세 명의 직원에게 고용 유인을 위한 주식 옵션을 부여했습니다. 이 옵션은 20,000주의 보통주를 주당 $1.66에 구매할 수 있는 권리를 부여하며, 이는 2024년 10월 31일의 종가와 일치합니다. 이 옵션은 4년에 걸쳐 발생합니다, 1년 후 25%가 발생하고 나머지 75%는 이후 분기별로 발생하며, 계속적인 고용을 조건으로 합니다. 이 옵션의 유효 기간은 10년이며, Nasdaq 상장 규칙 5635(c)(4)를 준수합니다.
Akebia Therapeutics (Nasdaq: AKBA) a accordé des options sur actions à trois nouveaux employés en tant qu'incitatif à l'emploi. Ces options permettent l'achat de 20 000 actions ordinaires au prix de $1,66 par action, correspondant au prix de clôture du 31 octobre 2024. Ces options se débloquent sur quatre ans, avec 25% se débloquant après un an et les 75% restants se débloquant trimestriellement par la suite, sous réserve d'un emploi continu. Les options ont une durée de 10 ans et respectent la règle 5635(c)(4) du Nasdaq.
Akebia Therapeutics (Nasdaq: AKBA) hat drei neu eingestellte Mitarbeiter Aktienoptionen als Arbeitsanreiz gewährt. Die Optionen ermöglichen den Kauf von 20.000 Aktien zu einem Preis von $1,66 pro Aktie, was dem Schlusskurs am 31. Oktober 2024 entspricht. Diese Optionen werden über vier Jahre fällig, wobei 25% nach einem Jahr und die verbleibenden 75% anschließend vierteljährlich fällig werden, vorausgesetzt, der Mitarbeiter bleibt angestellt. Die Optionen haben eine Laufzeit von 10 Jahren und entsprechen der Nasdaq-Listing-Regel 5635(c)(4).
- Employee retention strategy through stock options indicating company growth and hiring
- Potential future dilution of existing shareholders through stock option grants
The options have an exercise price of
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in
Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/akebia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302294414.html
SOURCE Akebia Therapeutics, Inc.
FAQ
How many shares were granted in Akebia Therapeutics (AKBA) October 2024 inducement grants?
What is the exercise price for AKBA's October 2024 inducement stock options?
What is the vesting schedule for AKBA's October 2024 inducement grants?
